SINOVAC Plans to Invest USD 100 Mn in Brazil Starting This Year

Healthcare Author: EqualOcean News Jun 06, 2024 06:18 PM (GMT+8)

EqualOcean has learned that on June 4, Vice President of the Federative Republic of Brazil and Minister of Development, Industry, Trade, and Services, Geraldo Alckmin, met with SINOVAC(科兴) Chairman, President, and CEO Yin Weidong(尹卫东) in Beijing.


Yin Weidong announced that SINOVAC plans to invest USD 100 million in Brazil starting this year. This investment will support collaborations with Brazilian partners and top scientists, not only in the vaccine sector but also in advanced fields such as cell therapy and monoclonal antibody drugs.

SINOVAC Biotech Ltd., founded in 2001 and headquartered in Beijing, is listed on the Nasdaq Global Select Market (Nasdaq-GS: SVA). Through its wholly-owned subsidiary Sinovac Biotech (Hong Kong) Ltd., SINOVAC owns multiple companies, including Sinovac Biotech Co., Ltd., Sinovac Life Sciences Co., Ltd., and Sinovac Vaccine Technology Co., Ltd. The company has four industrial bases in Haidian, Changping, Daxing (Beijing), and Dalian (Liaoning), and is advancing the research and industrialization of biopharmaceutical products in several countries.

With the mission to "provide vaccines to eliminate diseases for humans," SINOVAC is dedicated to the research, development, production, and sales of human vaccines and related products to support disease prevention and control. The company has undertaken nearly 60 national and local scientific research projects, received two national-level scientific and technological awards, three national society awards, and six provincial-level scientific and technological progress awards, and published over 140 papers in SCI journals. SINOVAC has filed more than 150 patents, with over 90 granted.

EqualOcean reports that SINOVAC places a high emphasis on R&D and innovation, having established academician workstations and a national postdoctoral research workstation. It is the host unit of the BRICS Vaccine R&D China Center and collaborates with numerous universities and research institutes domestically and internationally. The company's ongoing vaccine R&D projects, including rotavirus vaccines, DTP series combined vaccines, multivalent hand-foot-and-mouth disease vaccines, pneumococcal series vaccines, meningococcal series vaccines, and other respiratory and enteric infectious disease vaccines, are in clinical or pre-clinical stages.

SINOVAC primarily sells vaccines in the Chinese market while continuously exploring international opportunities. The company has supplied vaccines to dozens of countries and international organizations, contributing to disease prevention and control in China and globally.